FOXO4-DRI — 10mg per Vial

FOXO4-DRI is a rationally designed senolytic peptide built on a D-retro-inverso (DRI) modification that enhances its stability and cell permeability. It works by disrupting the interaction between the FOXO4 protein and the tumor-suppressor p53 — a binding event that senescent cells rely on to evade programmed cell death. By occupying the FOXO4 interface, FOXO4-DRI releases p53 and selectively triggers apoptosis in senescent cells, where FOXO4 is overexpressed, while comparatively sparing healthy proliferating cells. First brought to prominence by Baar et al. (Cell, 2017) and validated across naturally aged and progeroid mouse models, FOXO4-DRI remains one of the most studied peptide-based tools in cellular senescence, vascular aging, and longevity research.

Important Note

FOXO4-DRI is not approved for human consumption, medical use, or diagnostic purposes. It is supplied strictly for laboratory research only. Handling should be performed by qualified professionals in an appropriate controlled research setting.

Dosage Reference Chart (Research Use Only)

FormSuggested Research ConcentrationExample PreparationNotesLyophilized Powder10mg per vialReconstitute with sterile or bacteriostatic waterStore dry at –20°C until useReconstituted Solution1–5 mg/mLDissolve to target concentration for experimentsStable at 2–8°C for 2–3 weeks; do not freeze once reconstitutedExperimental DosingVariable by studyAdjust according to study designPreclinical / literature-based models only

Features & Properties

D-retro-inverso (DRI) modified peptide for enhanced stability and permeability

Studied for selective disruption of the FOXO4–p53 protein interaction

Examined for its role in releasing p53 to induce apoptosis in senescent cells

Investigated in naturally aged and progeroid mouse models

A focal compound in senolytic, cellular-senescence, and longevity research

Supplied as lyophilized powder for maximum stability during storage and transport

Manufactured under research-grade quality standards with HPLC-verified purity ≥99%

Storage & Stability

Lyophilized: stable for up to 24 months at –20°C

Reconstituted solution: stable for 2–3 weeks at 2–8°C

Avoid repeated freeze–thaw cycles

Protect from light and moisture at all times

Usage Restrictions

For laboratory research use only

Not approved for human consumption, medical use, or diagnostic purposes

Handling should be performed by qualified professionals in controlled research settings

Store securely and keep out of reach of children

Do not handle during pregnancy or breastfeeding

Frequently Asked Questions

Q1. What does each vial contain? Each vial contains 10mg of FOXO4-DRI peptide, supplied as a sterile lyophilized powder.

Q2. What is the appearance of the product? A fine white to off-white lyophilized powder at the base of the vial.

Q3. How should it be stored? Before reconstitution: store at –20°C, stable up to 24 months. After reconstitution: store refrigerated at 2–8°C, stable 2–3 weeks.

Q4. How is it reconstituted? It is soluble in sterile or bacteriostatic water. Use aseptic technique during reconstitution to maintain integrity.

Q5. Is it sterile? Yes, it is manufactured and sealed under sterile laboratory conditions. Proper sterile handling is still required during reconstitution and use.

Q6. Is this product for human use? No. This compound is intended for research use only. It is not approved for medical or veterinary use.

Q7. What purity standard is used? Every batch is HPLC-verified to ≥99% purity and third-party tested.

Q8. What is the vial packaging? A clear borosilicate glass vial sealed with a butyl rubber stopper and aluminum crimp closure.

Q9. How stable is the product during shipping? The lyophilized form is stable under standard shipping conditions. Transfer to long-term storage (–20°C) immediately upon arrival.

Q10. Who can handle this product? Only qualified laboratory researchers with appropriate training in peptide handling and proper protective equipment.